Baxters BAX 817 Tests Positive for Hemophilia Treatment - Zacks.com
/http://ift.tt/1wWyOpt Click to read full article...
Baxters BAX 817 Tests Positive for Hemophilia TreatmentZacks.comBaxter International Inc. (BAX - Analyst Report) recently revealed positive efficacy and safety data from its Phase III clinical trial evaluating BAX 817 – an investigational recombinant factor VIIa (rFVIIa) for hemophilia A or B patients who develop ...Baxter International Inc. (NYSE:BAX) on Watch ListMarkets WiredLarge Cap Stocks in the Spotlight - Baxter International (BAX), Colgate ...Techsonian (press release)all 4 news articles »
from Hemophilia - Google News http://ift.tt/1wWyOpt via IFTTT